MedTrace Logo

An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin

NCT00549887 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2459

Last updated 2010-03-16

No results posted yet for this study

Summary

The purpose of this study is to estimate the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and short-acting human insulin therapy within the first year following the switch. The additional goals are: 1)to assess the impact of a switch from or to a rapid-acting analog insulin therapy on patient treatment satisfaction, 2) to assess the impact of a switch from or to a rapid-acting analog insulin therapy on patient quality of life, 3) to assess the impact of switch from or to the rapid-acting analog insulin therapy on the quality of metabolic control and, 4) to estimate the total costs (direct and indirect) associated with switching, in either direction between rapid-acting analog and short-acting human insulin within the first year following the switch.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Analog or Human Insulin

prescribed in accordance with usual clinical practice

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Austria
  • Czechia
  • Germany
  • Greece
  • Hungary
  • Poland
  • Romania
  • Slovakia
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00549887 on ClinicalTrials.gov